PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma.
Saved in:
| Title: | PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma. |
|---|---|
| Authors: | Buckley, Hannah L.1 (AUTHOR), Collinson, Fiona J.1 (AUTHOR), Ainsworth, Gemma1 (AUTHOR), Poad, Heather1 (AUTHOR), Flanagan, Louise1 (AUTHOR), Katona, Eszter1 (AUTHOR), Howard, Helen C.1 (AUTHOR), Murden, Geraldine1 (AUTHOR), Banks, Rosamonde E.2 (AUTHOR), Brown, Joanne2 (AUTHOR), Velikova, Galina3 (AUTHOR), Waddell, Tom4 (AUTHOR), Fife, Kate5 (AUTHOR), Nathan, Paul D.6 (AUTHOR), Larkin, James7 (AUTHOR), Powles, Thomas8 (AUTHOR), Brown, Sarah R.1 (AUTHOR), Vasudev, Naveen S.2 (AUTHOR) N.Vasudev@leeds.ac.uk |
| Source: | BMC Cancer. 11/14/2019, Vol. 19 Issue 1, p1-9. 9p. 1 Diagram. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
